Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
1CMMILFF -32.49%46 Cash-to-Debt is 6.23 as of May. 2026, which is 889% above its 10-year median of 0.63. GuruFocus rates MILFF with a GF Score™ of 46/100 and a GF Value™ of $0.28 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 983 Drug Manufacturers companies, 1CM ranks better than 71.82% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. 1CM's cash to debt ratio for the quarter that ended in May. 2026 was 6.23.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, 1CMcould pay off its debt using the cash in hand for the quarter that ended in May. 2026.
The historical rank and industry rank for 1CM's Cash-to-Debt or its related term are showing as below:
MILFF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.63 Max: No Debt
Current: 6.23
During the past 13 years, 1CM's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.63.
MILFF's Cash-to-Debt is ranked better than 71.82% of 983
companies
in the Drug Manufacturers industry
Industry Median: 0.96
vs MILFF: 6.23
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
1CM Cash-to-Debt Related Terms
1CM Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for 1CM's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, 1CM's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
1CM Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, 1CM's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where 1CM's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1CM (MILFF) has a Cash-to-Debt of 6.23 as of May. 2026. This is 889% above median its historical median of 0.63. According to the industry distribution chart, 1CM ranks #277 out of 983 companies in the Drug Manufacturers industry, placing it in the top 28.2%.
Is 1CM's Cash-to-Debt too high?
1CM's current Cash-to-Debt of 6.23 is 889% above median its 10-year median of 0.63. The Drug Manufacturers industry median Cash-to-Debt is 0.96. 1CM's value of 6.23 is 549% above this industry median. Based on the distribution chart, 1CM ranks #277 out of 983 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, 1CM has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 1CM's Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, 1CM ranks #277 out of 983 companies for Cash-to-Debt. This puts 1CM in the upper half of its industry. The industry median Cash-to-Debt is 0.96. 1CM's value of 6.23 is 549% above this benchmark. While the company's 10-year median is 0.63 vs. the industry median of 0.96, 1CM has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.96, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 1CM's current Cash-to-Debt of 6.23 is 549% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 1CM's current Cash-to-Debt is 6.23, which is 889% above median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 1CM stock overvalued right now?
Based on GuruFocus' analysis, 1CM (MILFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.28, compared to a current price of $0.22 — trading 20.2% below its estimated fair value. The current Cash-to-Debt is 6.23, which is 889% above median its 10-year median of 0.63 and 549% above the Drug Manufacturers industry median of 0.96. 1CM's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For 1CM (MILFF), the current Cash-to-Debt is 6.23 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 1CM (MILFF) Overvalued in 2026?
Based on GuruFocus' analysis, 1CM stock appears to be undervalued.
The current stock price of $0.22 is trading 20.2% below its estimated GF Value™ of $0.28.
GuruFocus considers 1CM to be Modestly Undervalued.
Key valuation signals for MILFF:
Cash-to-Debt: 6.23 (889% above median its 10-year median of 0.63)
GF Value™: $0.28 vs. price of $0.22 (20.2% below fair value)
Industry Position: 549% above the Drug Manufacturers median (#277 of 983)
No single metric tells the full story. See the MILFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
1CM Inc is a multi-jurisdictional cannabis company focused on its retail customers and technology to democratize cannabis markets. The Company focuses on expanding its current operations through organic growth and by way of merger and acquisition transactions. It has a single operating segment, being Cannabis.
46GF Score
Get the complete analysis for MILFF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MILFF has been successfully added to your 
